Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia

Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60. It is defined by motor and nonmotor symptoms including a spectrum of cognitive impairments known as Parkinson’s disease dementia (PDD). Currently, the only US Food and Drug Administra...

Full description

Bibliographic Details
Main Authors: Emma D. Frost, Swanny X. Shi, Vishnu V. Byroju, Jamir Pitton Rissardo, Jack Donlon, Nicholas Vigilante, Briana P. Murray, Ian M. Walker, Andrew McGarry, Thomas N. Ferraro, Khalid A. Hanafy, Valentina Echeverria, Ludmil Mitrev, Mitchel A. Kling, Balaji Krishnaiah, David B. Lovejoy, Shafiqur Rahman, Trevor W. Stone, Maju Mathew Koola
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Brain Sciences
Subjects:
cognition
drug combination
galantamine
kynurenic acid
memantine
<i>N</i>-acetylcysteine
Online Access:https://www.mdpi.com/2076-3425/14/12/1163

Internet

https://www.mdpi.com/2076-3425/14/12/1163

Similar Items